News Column

Reports on Chemotherapy from East China University of Science and Technology Provide New Insights

June 4, 2014

By a News Reporter-Staff News Editor at Biotech Week -- Researchers detail new data in Drugs and Therapies. According to news reporting originating from Shanghai, People's Republic of China, by NewsRx correspondents, research stated, "In vivo monitoring of the biodistribution and activation of prodrugs is urgently required. Near infrared (NIR) fluorescence-active fluorophores with excellent photostability are preferable for tracking drug release in vivo."

Our news editors obtained a quote from the research from the East China University of Science and Technology, "Herein, we describe a NIR prodrug DCM-S-CPT and its polyethylene glycol-polylactic acid (PEG-PLA) loaded nanoparticles as a potent cancer therapy. We have conjugated a dicyanomethylene-4H-pyran derivative as the NIR fluorophore with camptothecin (CPT) as the anticancer drug using a disulfide linker. In vitro experiments verify that the high intracellular glutathione (GSH) concentrations in tumor cells cause cleavage of the disulfide linker, resulting in concomitantly the active drug CPT release and significant NIR fluorescence turn-on with large Stokes shift (200 nm). The NIR fluorescence of DCM-S-CPT at 665 nm with fast response to GSH can act as a direct off-on signal reporter for the GSH-activatable prodrug. Particularly, DCM-S-CPT possesses much better photostability than ICG, which is highly desirable for in situ fluorescence-tracking of cancer chemotherapy. DCM-S-CPT has been successfully utilized for in vivo and in situ tracking of drug release and cancer therapeutic efficacy in living animals by NIR fluorescence. DCM-S-CPT exhibits excellent tumor-activatable performance when intravenously injected into tumor-bearing nude mice, as well as specific cancer therapy with few side effects. DCM-S-CPT loaded in PEG-PLA nanoparticles shows even higher antitumor activity than free CPT, and is also retained longer in the plasma."

According to the news editors, the research concluded: "The tumor-targeting ability and the specific drug release in tumors make DCM-S-CPT as a promising prodrug, providing significant advances toward deeper understanding and exploration of theranostic drug-delivery systems."

For more information on this research see: In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug. Journal of the American Chemical Society, 2014;136(9):3579-88. (American Chemical Society -; Journal of the American Chemical Society -

The news editors report that additional information may be obtained by contacting X. Wu, Key Laboratory for Advanced Materials and Institute of Fine Chemicals, Shanghai Key Laboratory of Functional Materials Chemistry, East China University of Science and Technology , Shanghai 200237, People's Republic of China. Additional authors for this research include X. Sun, Z. Guo, J. Tang, Y. Shen, T.D. James, H. Tian and W. Zhu (see also Drugs and Therapies).

Keywords for this news article include: Asia, Cancer, Shanghai, Oncology, Chemotherapy, Nanoparticle, Nanotechnology, Drugs and Therapies, Emerging Technologies, People's Republic of China.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters